Quantcast

Latest Telik Inc. Stories

2011-08-11 15:05:00

PALO ALTO, Calif., Aug. 11, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $3.0 million, or $0.06 per share, for the second quarter ended June 30, 2011, compared with a net loss of $4.9 million, or $0.09 per share, for the comparable period in 2010. For the quarter ended June 30, 2011, total operating costs and expenses were $3.0 million, compared with $5.0 million in the 2010 second quarter. Operating expenses in the 2011 second quarter included stock-based...

2011-06-07 15:05:00

PALO ALTO, Calif., June 7, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced the initiation of a Phase 2 clinical trial to evaluate oral Telintra in patients with Revlimid refractory or resistant, deletion 5q myelodysplastic syndrome (del 5q MDS). This is a multicenter trial intended to enroll up to 117 evaluable patients. It employs a sequential design with two interim analyses. These patients are transfusion dependent with Low to Intermediate-1 Risk MDS. Telintra will be...

2011-05-16 15:05:00

PALO ALTO, Calif., May 16, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2011. The net loss for the quarter ended March 31, 2011 was $3.7 million, or $0.07 per share, compared with a net loss of $5.3 million, or $0.10 per share, for the same period in 2010. Total research and development expenses (R&D) in the first quarter of 2011 were $1.7 million, compared to $2.8 million for the same period in 2010. The...

2011-04-05 07:00:00

PALO ALTO, Calif., April 5, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today presented data at the 102nd American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida on a group of second generation analogs of ezatiostat, the most clinically advanced product in development at Telik. Ezatiostat is the first inhibitor of glutathione-S-transferase P1-1 (GST P-1), a validated enzyme target in Myelodysplastic Syndrome (MDS), to successfully complete a Phase 2 clinical...

2011-03-30 15:05:00

PALO ALTO, Calif., March 30, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate overview at the 10th Annual Needham Healthcare Conference in New York City on Wednesday, April 6 at 11:20 a.m. Eastern time (8:20 a.m. Pacific time), in the New York Palace Hotel's Henry's Suite. A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. The archived broadcast of the...

2011-03-25 18:31:00

PALO ALTO, Calif., March 25, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced that a presentation titled: "Synthesis and biochemical characterization of novel analogues of ezatiostat hydrochloride (TLK199, Telintra®)" will be given at the 102nd annual meeting of the American Association for Cancer Research (AACR) in Orlando, Florida. The presentation will be made on Tuesday, April 5th, 2011 from 8:00 am - 12:00 pm in Exhibit Hall A4-C, Poster Section; Cancer...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.